Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Drugs under Simultaneous Global Development May also Be Eligible for New Fast-Track Review System: MHLW Exec
June 26, 2014
-
ACADEMIA Univ. Says Data Leaks in SIGN Run Afoul of Personal Information Law, Newly Finds Bristol’s Misconduct
June 25, 2014
-
BUSINESS Plavix Grabs Top Spot in FY2013 Domestic Ethical Drug Sales Ranking
June 24, 2014
-
BUSINESS Probe Finds Takeda’s Systematic Involvement in CASE-J Study, No Data Tampering
June 23, 2014
-
REGULATORY First Generics of Diovan, Blopress AGs Join Reimbursement List
June 20, 2014
-
BUSINESS Takeda Ceases Development of TAK-700 for Prostate Cancer on Lackluster PIII Results
June 20, 2014
-
BUSINESS Japan Vaccine President and Chairman Swap Posts
June 19, 2014
-
REGULATORY LDP Members Request Govt to Stay with Current Biennial NHI Price Revision
June 18, 2014
-
BUSINESS Sawai Seeks US Approval for Livalo Generic, Submits ANDA
June 17, 2014
-
ORGANIZATION Japan Diabetes Group Announces Recommendations on Proper Use of SGLT-2 Inhibitors
June 17, 2014
-
REGULATORY “Annual” NHI Price Revision Erased from Gov’t Draft Policy Blueprint
June 16, 2014
-
BUSINESS AZ to Shuffle Sales, Marketing Units, Focus on 3 Disease Areas
June 16, 2014
-
BUSINESS Takeda Debuts Aspirin-PPI Combination Drug Takelda in Japan
June 13, 2014
-
REGULATORY LDP Members with Vested Interests Slam Annual NHI Price Revision
June 12, 2014
-
BUSINESS Nippon Shinyaku to Concentrate Sales Force in Three Therapeutic Fields
June 11, 2014
-
REGULATORY Ex-Novartis Employee Nabbed over Diovan Data Tampering: Reports
June 11, 2014
-
REGULATORY Govt Tilting Toward Etching Annual NHI Price Revision in Fiscal Blueprint
June 10, 2014
-
ORGANIZATION Generic Versions of Combination Drug Exforge to Be Named “Amvalo”: JSGM
June 10, 2014
-
REGULATORY Researchers Aiming to Craft Guide for Ultra-Orphan Drug Development
June 9, 2014
-
REGULATORY MHLW, Pharma Officials Take to Nagata-cho in Crusade against Yearly NHI Price Revision
June 6, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…